Pharmacy Policy Updates November 2026The following policies are effective December 1, 2026CareSource Dual Advantage (HMO D-SNP) CareSource Dual Advantage Plus (HMO D-SNP) 2 Y0119_GA-SNP-P -6403251_C | Policy Updates Network Notification | November 2026AT CARESOURCE, WE LISTEN TO OUR PROVIDERS, AND WE STREAMLINE OUR BUSINESS PRACTICES TO MAKE IT EASIER FOR YOU TO WORK WITH US. We have worked to create a predictable cycle for releasing administrative, pharmacy, and reimbursement policies, so you know wha t to expect.Check back each month for a consolidated network notification of policy updates from CareSource.HOW TO USE THIS NETWORK NOTIFICATION Reference the list of policy updates. Note the effective date and impacted plans for each policy. Click the hyperlinked policy title to open the webpage containing the policy location. FIND OUR POLICIES ONLINETo access all CareSource policies, visit CareSource.com > Providers > Tools & Resources > Provider Policies . Select your plan and state, then Pharmacy, Reimbursement, or Administrative. Each policy page has an archive where you can find previous versions of policies. PHARMACY POLICY UPDATES3 Y0119_GA-SNP-P -6403251_C | Policy Updates Network Notification | November 2026 POLICY NAME EFFECTIVE DATE PLAN IMPACT Botox ( onabotulinumtoxinA injection Allergan/AbbVie) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONDysport ( abobotulinumtoxinA injection Ipsen/Galderma)DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCEMI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONMyobloc ( rimabotulinumtoxinB injection Solstice) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONXeomin ( incobotulinumtoxinAinjection Merz) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONArmlupeg ( pegfilgrastim-unne subcutaneous injection Lupin)DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCEMI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONPHARMACY POLICY UPDATES4 Y0119_GA-SNP-P -6403251_C | Policy Updates Network Notification | November 2026 POLICY NAME EFFECTIVE DATE PLAN IMPACT Fulphila (pegfilgrastim-jmdb subcutaneous injection Mylan)DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCEMI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONFylnetra ( pegfilgrastim-pbbk subcutaneous injection Amneal )DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONNeulasta ( pegfilgrastim subcutaneous injection Amgen) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONNyvepria ( pegfilgrastim-apgf subcutaneous injection Pfizer)DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONStimufend ( pegfilgrastim-fpgk subcutaneous injection Fresenius Kabi)DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCEMI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISION5 Y0119_GA-SNP-P -6403251_C | Policy Updates Network Notification | November 2026 POLICY NAME EFFECTIVE DATE PLAN IMPACT Udenyca (pegfilgrastim-cbqv subcutaneousinjection Coherus )DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONZiextenzo ( pegfilgrastim-bmez subcutaneousinjection Sandoz)DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONAranesp (darbepoetin alfa intravenous or subcutaneous injection Amgen) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONGenglycos ( pariglasgene brecaparvovec-opnr intravenous infusion Ultragenyx) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)NEW POLICYSupprelin LA ( histrelin acetate subcutaneous implant Endo) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONZoladex (goserelin acetate subcutaneous implant TerSera Therapeutics) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISION6 Y0119_GA-SNP-P -6403251_C | Policy Updates Network Notification | November 2026 POLICY NAME EFFECTIVE DATE PLAN IMPACT Lupron Depot (leuprolide acetate suspension for intramuscular injection AbbVie) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONTregzi (allogeneic regulatory Tcell immunotherapy with HSPS and Tcells-vldq DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONCasgevy ( exagamglogene autotemcel intravenous infusion Vertex/CRISPR DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONLeqvio (inclisiran subcutaneous injection Novartis) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONOmvoh ( mirikizumab-mrkz intravenousinfusion Eli Lilly)DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISION7 Y0119_GA-SNP-P -6403251_C | Policy Updates Network Notification | November 2026 POLICY NAME EFFECTIVE DATE PLAN IMPACT Orencia ( abatacept intravenous infusion Bristol Myers Squibb) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONActemra (tocilizumab intravenous infusion Genentech/Roche) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONAvtozma (tocilizumab-anoh intravenous infusion Celltrion) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONTofidence (tocilizumab-bavi intravenous infusion Biogen) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONTyenne (tocilizumab-aazg intravenousinfusion Fresenius Kabi)DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISION8 Y0119_GA-SNP-P -6403251_C | Policy Updates Network Notification | November 2026 POLICY NAME EFFECTIVE DATE PLAN IMPACT Stelara (ustekinumab intravenous infusion Janssen Biotech) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONImuldosa (ustekinumab-srlf intravenous infusion Accord)DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONOtulfi (ustekinumab-aauz intravenous infusion Formycon /Fresenius)DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONPyzchiva (ustekinumab-ttwe intravenous infusion Sandoz/Samsung) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISION9 Y0119_GA-SNP-P -6403251_C | Policy Updates Network Notification | November 2026 POLICY NAME EFFECTIVE DATE PLAN IMPACT Selarsdi (ustekinumab-aekn intravenous infusion Alvotech /Teva)DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONStarjemza (ustekinumab-hmny intravenous infusion BioThera ) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONSteqeyma (ustekinumab-stba intravenous infusion Celltrion) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONWezlana (ustekinumab-auub intravenous infusion Amgen) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONYesintek (ustekinumab-kfce intravenous infusion Biocon) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISION10 Y0119_GA-SNP-P -6403251_C | Policy Updates Network Notification | November 2026 POLICY NAME EFFECTIVE DATE PLAN IMPACT Ustekinumab intravenous infusion (Janssen Biotech) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONUstekinumab-ttwe intravenous infusion ( Quallent ) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONInjectafer (ferric carboxymaltose intravenous infusion or slow injection American DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONFayuvi ( rebisufligene etisparvovec-hopf intravenous infusion Ultragenyx) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)NEW POLICY11 Y0119_GA-SNP-P -6403251_C | Policy Updates Network Notification | November 2026 POLICY NAME EFFECTIVE DATE PLAN IMPACT Imaavy ( nipocalimab-aahu intravenous infusion Johnson & Johnson)DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONZanvastro ( zilganersen intrathecal injection Ionis) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONElrexfio ( elranatamab-bcmm subcutaneous injection Pfizer) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONTecvayli ( teclistamab-cqyv subcutaneousinjection Janssen Biotech)DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONTalvey ( talquetamab-tgvs subcutaneousinjection Janssen Biotech)DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONPHARMACY POLICY UPDATES12 Y0119_GA-SNP-P -6403251_C | Policy Updates Network Notification | November 2026 POLICY NAME EFFECTIVE DATE PLAN IMPACT Yervoy (ipilimumab intravenous infusion Bristol-Myers Squibb) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONKeytruda (pembrolizumab intravenous infusion Merck) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONKeytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph subcutaneousDECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCEMI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONOpdivo (nivolumab intravenous infusion Bristol-Myers Squibb) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONOpdivo Qvantig (nivolumab and hyaluronidase-nvhy subcutaneous injection DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISION13 Y0119_GA-SNP-P -6403251_C | Policy Updates Network Notification | November 2026 POLICY NAME EFFECTIVE DATE PLAN IMPACT Faslodex (fulvestrant intramuscular injection AstraZeneca, generic)DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCEMI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONCligavyx (fulvestrant intramuscular injection Avyxa ) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCEMI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONNipent (pentostatin intravenous infusion Hospira) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONIsembyld ( apitegromab-mstn intravenous infusion Scholar Rock)DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCEMI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)NEW POLICYPHARMACY POLICY UPDATES14 Y0119_GA-SNP-P -6403251_C | Policy Updates Network Notification | November 2026 POLICY NAME EFFECTIVE DATE PLAN IMPACT Pluvicto (lutetium Lu 177 vipivotide tetraxetan intravenous infusion Advanced DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONPoteligeo (mogamulizumab-kpkc intravenous infusion Kyowa Kirin) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONTudriqev ( vusolimogene oderparepvec-wtpg suspension for intratumor injection DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)NEW POLICYZiihera ( zanidatamab-hrii intravenousinfusion Jazz)DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONInlexzo (gemcitabine intravesical system Janssen/Johnson and Johnson) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONPHARMACY POLICY UPDATES15 Y0119_GA-SNP-P -6403251_C | Policy Updates Network Notification | November 2026 POLICY NAME EFFECTIVE DATE PLAN IMPACT Otarmeni ( lunsotogene parvec-cwha intracochlear infusion Regeneron) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONRiabni (rituximab-arrx intravenousinfusion Amgen)DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONRituxan (rituximab intravenous infusion Genentech) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONRuxience (rituximab-pvvr intravenous infusion Pfizer) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONTruxima (rituximab – abbs intravenous infusion Celltrion/Teva) DECEMBER 1, 2026 CARESOURCE MYCARE OHIO (MEDICARE-MEDICAID PLAN) HAP CARESOURCE MI COORDINATED HEALTH (HMO D-SNP) CARESOURCE DUAL ADVANTAGE(HMO D-SNP) CARESOURCE DUAL ADVANTAGEPLUS (HMO D-SNP)REVISIONPHARMACY POLICY UPDATES POLICY NAMEEFFECTIVE DATE PLAN IMPACTArmlupeg ( pegfilgrastim-unne subcutaneous injection Lupin) DECEMBER 1, 2026 CARESOURCE DUAL ADVANTAGE (HMO D-SNP) CARESOURCE DUAL ADVANTAGE PLUS (HMO D-SNP)REVISIONFulphila ( pegfilgrastim-jmdb subcutaneousinjection-Mylan)DECEMBER 1, 2026 CARESOURCE DUAL ADVANTAGE (HMO D-SNP) CARESOURCE DUAL ADVANTAGE PLUS (HMO D-SNP)REVISIONFylnetra ( pegfilgrastim-pbbk subcutaneous injection-Kashiv ) DECEMBER 1, 2026 CARESOURCE DUAL ADVANTAGE (HMO D-SNP) CARESOURCE DUAL ADVANTAGE PLUS (HMO D-SNP)REVISIONNeulasta (pegfilgrastim subcutaneous injection-Amgen) DECEMBER 1, 2026 CARESOURCE DUAL ADVANTAGE (HMO D-SNP) CARESOURCE DUAL ADVANTAGE PLUS (HMO D-SNP)REVISIONNyvepria ( pegfilgrastim-apgf subcutaneous injection Pfizer) DECEMBER 1, 2026 CARESOURCE DUAL ADVANTAGE (HMO D-SNP) CARESOURCE DUAL ADVANTAGE PLUS (HMO D-SNP)REVISIONStimufend ( pegfilgrastim-fpgk subcutaneous injection Fresenius Kabi) DECEMBER 1, 2026 CARESOURCE DUAL ADVANTAGE (HMO D-SNP) CARESOURCE DUAL ADVANTAGE PLUS (HMO D-SNP)REVISION16 Y0119_GA-SNP-P -6403251_C | Policy Updates Network Notification | November 2026 PHARMACY POLICY UPDATES POLICY NAMEEFFECTIVE DATE PLAN IMPACTUdenyca ( pegfilgrastim-cbqv subcutaneous injection Coherus ) DECEMBER 1, 2026 CARESOURCE DUAL ADVANTAGE (HMO D-SNP) CARESOURCE DUAL ADVANTAGE PLUS (HMO D-SNP)REVISIONZiextenzo ( pegfilgrastim-bmez subcutaneous injection Sandoz) DECEMBER 1, 2026 CARESOURCE DUAL ADVANTAGE (HMO D-SNP) CARESOURCE DUAL ADVANTAGE PLUS (HMO D-SNP)REVISIONAranesp (darbepoetin alfa intravenous or subcutaneous injection-Amgen) DECEMBER 1, 2026 CARESOURCE DUAL ADVANTAGE (HMO D-SNP) CARESOURCE DUAL ADVANTAGE PLUS (HMO D-SNP)REVISIONSupprelin LA ( histrelin acetate subcutaneous implant Endo Pharmaceuticals) DECEMBER 1, 2026 CARESOURCE DUAL ADVANTAGE (HMO D-SNP) CARESOURCE DUAL ADVANTAGE PLUS (HMO D-SNP)REVISIONZoladex (goserelin acetate subcutaneous implant TerSera Therapeutics) DECEMBER 1, 2026 CARESOURCE DUAL ADVANTAGE (HMO D-SNP) CARESOURCE DUAL ADVANTAGE PLUS (HMO D-SNP)REVISION17 Y0119_GA-SNP-P -6403251_C | Policy Updates Network Notification | November 2026 PHARMACY POLICY UPDATES POLICY NAMEEFFECTIVE DATE PLAN IMPACTAlyglo (immune globulin intravenous solution-stwk GC Biopharma) DECEMBER 1, 2026 CARESOURCE DUAL ADVANTAGE (HMO D-SNP) CARESOURCE DUAL ADVANTAGE PLUS (HMO D-SNP)REVISIONAsceniv (immune globulin intravenous solution-sira ADMA Biologics ) DECEMBER 1, 2026 CARESOURCE DUAL ADVANTAGE (HMO D-SNP) CARESOURCE DUAL ADVANTAGE PLUS (HMO D-SNP)REVISIONBivigam (immune globulin intravenous solution AMDA Biologics ) DECEMBER 1, 2026 CARESOURCE DUAL ADVANTAGE (HMO D-SNP) CARESOURCE DUAL ADVANTAGE PLUS (HMO D-SNP)REVISIONFlebogamma DIF (immune globulin intravenous solution Grifols) DECEMBER 1, 2026 CARESOURCE DUAL ADVANTAGE (HMO D-SNP) CARESOURCE DUAL ADVANTAGE PLUS (HMO D-SNP)REVISIONGammagard Liquid (immune globulin solution Baxalta [Takeda]), Gammagard Liquid ERC (immune globulin solution Baxalta [Takeda]) DECEMBER 1, 2026 CARESOURCE DUAL ADVANTAGE (HMO D-SNP) CARESOURCE DUAL ADVANTAGE PLUS (HMO D-SNP)REVISION18 Y0119_GA-SNP-P -6403251_C | Policy Updates Network Notification | November 2026 PHARMACY POLICY UPDATES POLICY NAMEEFFECTIVE DATE PLAN IMPACT Gammagard S/D
Medicare Advantage Medical Utilization Review Policy 09/28/2026 Express Scripts S trategic Development, Inc., 2026 . All Rights Reserved. This document is confidential and proprietary to Express Scripts Strategic Development, Inc. Unauthorized use and distribution are prohibited.Policy: Gonadotropin-Releasing Hormone Agonists – Implants Utilization Management MedicalPolicy Supprelin LA (histrelin acetate subcutaneous implant Endo Pharmaceuticals) Zoladex (goserelin acetate subcutaneous implant TerSera Therapeutics) Date: 09/28/2026 Applicable Lines of Business: Medicare Advantage – Medical Applicable States: Palmetto, JJ: Alabama, Georgia, Tennessee Palmetto, JM: North Carolina, South Carolina, Virginia, West Virginia Applicable NCDs, LCDs, and/or LCAs L39387, A59160 Note: Supprelin LA is not addressed in Local Coverage Article A 59160 or Local CoverageDetermination L39387. SUMMARY OF EVIDENCESupprelin LA and Zoladex are gonadotropin-releasing hormone (GnRH) agonists implants. 1-3Supprelin LA is indicated for the treatment of central precocious puberty in children .1Zoladex is indicated for the following conditions: 2,3 Breast cancer , palliative treatment of advanced breast cancer in pre-and perimenopausal women (Zoladex 3.6 mg implant only). Endometrial-thinning , use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding (Zoladex 3.6 mg implant only). Endometriosis , including pain relief and reduction of endometriotic lesions for the duration of therapy (Zoladex 3.6 mg implant only). Labeling notes that experience with Zoladex for this indication has been limited to women 18 years of age. 2 Prostate cancer , in combination with flutamide for the management of locally confined Stage T2b-T4 (Stage B2-C). Prostate cancer , advanced carcinoma or palliative treatment. Zoladex 3.6 mg (equivalent to 3.8 mg goserelin acetate) is approved for all the diagnoses above . Zoladex10.8 mg (equivalent to 11.3 mg goserelin acetate) is only indicated for prostate cancer.GuidelinesCentral precocious puberty , also known as gonadotropin-dependent precocious puberty, is caused by early maturation of the hypothalamic-pituitary-gonadal axis. 5 The standard of care for central precocious puberty is GnRH agonists. The European Society for Paediatric Endocrinology and the Lawson Wilkins Pediatric Endocrine Society convened a consensus conference (2009) to review the use of GnRH agonists in pedia tric patients with central precocious puberty. 6 The panel noted that the available GnRH agonists (including leuprolide, triptorelin, and histrelin implants) are effective despite different routes of administration, dosing, and duration of action. An update by the International Consortium (2019) reite rates the use of GnRH agonists (e.g., leuprolide, triptorelin, and histrelin implants) for the treatment of central precocious puberty. 7 GnRH agonists are generally well-tolerated in children and adolescents. Gonadotropin-Relea sing Hormone Agonists Implants MA Medical UM Policy Page 2 09/28/2026 Express Scripts S trategic Development, Inc., 2026 . All Rights Reserved. This document is confidential and proprietary to Express Scripts Strategic Development, Inc. Unauthorized use and distribution are prohibited.Endometrosis: Care pathways available from American Family Physician (2022) recommend estrogen – progestin combination products or progestins as first-line medical therapies for endometriosis. 21 Second – line treatment consists of GnRH receptor agonists or antagonists. Aromatase inhibitors are reserved for severe disease. Gender-dysphoric/gender-incongruent persosns: According to the Endocrine Society Guidelines for thetreatment of gender dysphoric/gender-incongruent persons and the World Professional Association forTransgender Health, GnRH agonists can be used off-label for the treatment of gender-dysphoric/gender – incongruent persons to suppress physical changes of puberty and gonadal function. 17,18 Pubertal hormonal suppression should typically be initiated after the adolescent first exhibits physical changes of puberty (Tanner stages G2/B2). An advantage to using a GnRH analog is that the effects can be reversed; pubertal suppression can be disco ntinued if the individual no longer wishes to transition. Upon discontinuation of therapy, spontaneous pubertal development has been shown to resume. GnRH analogs can also be used in patients during late puberty to suppress the hypothalamic-pituitary-gon adal axis to allow for lower doses of cross-sex hormones. 19 In addition to use in adolescents, GnRH analog therapy is also used in adults, particularly male-to-female patients. 13 In addition to the approved indications, GnRH agonists have been used for other conditions. The National Comprehensive Cancer Network (NCCN) guidelines address the use of GnRH agonists in a number of guidelines: Adolescent and young adult oncology NCCN guidelines (version 2.2026 February 27 , 202 6)note GnRH agonists may be used in (oncology) protocols that are predicted to cause prolonged thrombocytopenia and present a risk for menorrhagia. 20 There are some limited data on GnRH agonists to preserve ovarian function during chemotherapy and some have shown that GnRH agonists may be beneficial for fertility preservation, although the guidelines note further investigation is needed and other fert ility preservation modalities should still be pursued. Breast cancer: The NCCN breast cancer guidelines (version 1.202 6 January 16 , 202 6) note methods for ovarian function suppression in breast cancer includes goserelin 3.6 mg subcutaneous every 4 weeks or 10.8 mg subcutaneous every 12 weeks. 4 Other previous information from NCCN regarding goserelin in breast cancer is under discussion. Head and neck cancer salivary gland tumors: The NCCN head and neck cancer guidelines (version 1.2026 December 8, 2025) notes that goserelin (category 2B) is useful for androgen receptor positive salivary gland tumors which are recurrent, unresectable, or metastatic. 9,11 Goserelin can also be used (category 2A) with abiraterone and prednisone. Dosing used in NCCN references was 3.6 mg subcutaneously once every 28 days. 14-16 Ovarian cancer, including fallopian tube cancer and primary peritoneal cancer: The NCCN ovarian cancer guidelines (version 3.2025 July 16, 2025) notes goserelin as other hormone therapy options for endometrioid carcinoma, low-grade serous carcinoma, malignant sex cord stromal tumors (for granulosa cell tumors), and recurrence therapy for platinum-sensitive disease. 9,12 Goserelin is an option for hormonal therapy. Prostate cancer: The NCCN prostate cancer guidelines (version 5.202 6 January 23 , 202 6) list goserelin , leuprolide, and triptorelin as androgen deprivation therapy options for use in various settings: clinically localized disease, regional disease, positive lymph nodes and/or adverse features post-radical prostatectomy, first persistence/recurrence, castration-sensitive disease, metastatic castration-sensitive disease , and castration-resistant disease .8 Uterine cancer: The NCCN uterine neoplasm guidelines (version 2.2026 November 14, 2025) notes that prescribers may consider GnRH analogs with aromatase inhibitors in patients who are premenopausal and not suitable for surgery for low-grade endometrial stromal sarcoma, adenosarcoma without sarcomatous overgrowth, or hormone receptor-positive uterine sarcomas. 9,10 Gonadotropin-Relea sing Hormone Agonists Implants MA Medical UM Policy Page 3 09/28/2026 Express Scripts S trategic Development, Inc., 2026 . All Rights Reserved. This document is confidential and proprietary to Express Scripts Strategic Development, Inc. Unauthorized use and distribution are prohibited.ANALYSIS OF EVIDENCEThe information provided in the summary of evidence is supported by labeled indications, CMS-approved compendia, published clinical literature, clinical practice guidelines, and/or applicable National Coverage Determinations (NCDs) , Local Coverage Determinations (LCDs) , and Local Coverage Articles (LCAs). Refer to the Sources of Information section of this policy for additional information. POLICY STATEMENTPrior authorization is recommended for medical benefit coverage of Supprelin LA and Zoladex . Approval is recommended for those who meet the Criteria and Dosing for the listed indication(s). Extended approvals are allowed if the patient continues to meet the Criteria and Dosing. All approvals are provided for the duration noted below. This policy incorporates Medicare coverage guidance as set forth in National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs), as well as in companion policy articles and other guidance applicable to the relevant service areas. Thes e documents are cited in the Sources of Informationsection of this policy. In some cases, this guidance includes specific lists of HCPCS and ICD-10 codes to help inform the coverage determination process. The Articles that include specific lists for billing and coding purposes will be included in the Sources of Information section of this policy. However, to the extent that this policy cites such lists of HCPCS and ICD-10 codes, they should be used for reference purposes only. The presence of a specific HCPCS or ICD-10 code in a chart or companion article to an LCD is not by itself sufficient to a pprove coverage. Similarly, the absence of such a code does not necessarily mean that the applicable condition or diagnosis is excluded from coverage. Note : Conditions for coverage outlined in this Medicare Advantage Medical Policy may be less restrictivethan those found in applicable National Coverage Determinations, Local Coverage Determinations and/or Local Coverage Articles. Examples of situations where this clinical policy may be less restrictive include,but are not limited to, coverage of additional indications supported by CMS-approved compendia and the exclusion from this policy of additional coverage criteria requirements outlined in applicable Nat ional Coverage Determinations, Local Coverage Determinations and/or Local Coverage Articles. Indications with a ^ below are referenced in both the corresponding Standard Medical UtilizationManagement Internal Policy AND applicable National Coverage Determinations (NCDs), Local CoverageDeterminations (LCDs), and/or Local Coverage Articles (LCAs). Coverage criteria for these indications may be internally developed and/or referenced in applicable NCDs, LCDs, and/or LCAs. For these indications, internally developed coverage criteria is denoted throughout the policy in the following manner: 1 ) IC-L ( internal criteria supported by the labeled indication ), 2) IC-COMP (internal criteria supported by CMS-approved compendia), 3) IC-ISGP (internal criteria intended to interpret or supplement general provisions outlined in applicable NCDs, LCDs, and/or LCAs), or 4) IC-EC (internal criteria intended to expand coverage beyond the coverage outlined in applicable NCDs, LCDs, and/or LCAs ). For these indications, coverage criteria that is NOT denoted with one of the above indicators is referenced in applicable NCDs, LCDs, and/or LCAs . Additional information supporting the rationale for determination of internal coverage criteria can be found via the Sources of Information section. Indications with a @ below are referenced in the corresponding Standard Medical Utilization ManagementInternal Policy , but are NOT directly referenced in applicable National Coverage Determinations (NCDs),Local Coverage Determinations (LCDs), and/or Local Coverage Articles (LCAs) . Coverage criteria for Gonadotropin-Relea sing Hormone Agonists Implants MA Medical UM Policy Page 4 09/28/2026 Express Scripts S trategic Development, Inc., 2026 . All Rights Reserved. This document is confidential and proprietary to Express Scripts Strategic Development, Inc. Unauthorized use and distribution are prohibited.these indications is internally developed. These indications and their respective coverage criteria represent expanded coverage beyond the coverage outlined in applicable NCDs, LCDs, and/or LCAs . Indications with a # below are supported and referenced in applicable National Coverage Determinations(NCDs), Local Coverage Determinations (LCDs), and/or Local Coverage Articles (LCAs) , but are NOTdirectly referenced in the corresponding Standard Medical Utilization Management Internal Policy . Coverage criteria for these indications is referenced in applicable NCDs, LCDs, and/or LCAs . Indications noted with eviCore are managed by eviCore healthcare for those clients who use eviCore foroncology and/or oncology-related reviews. For these indications, a prior authorization should be initiated through eviCore at www.eviCore.com . RECOMMENDED AUTHORIZATION CRITERIAI. Coverage of Supprelin LA is recommended in patients who meet the following criteria:FDA-Approved Indication1. Central Precocious Puberty. ^Criteria. Approve for 1 year.Dosing. Approve one implant (50 mg) once every 12 months (inserted subcutaneously in the upper arm ). Other Uses with Supportive Evidence2. Gender Dysphoric/Gender-Incongruent Persons; Persons Undergoing Gender Reassignment(Female-To-Male [FTM] or Male-to-Female [MTF]) . @ Criteria. Approve for 1 year .Dosing . Approve one implant (50 mg) once every 12 months (inserted subcutaneously in the upper arm). II. Coverage of Zoladex is recommended in patients who meet one of the following criteria:FDA-Approved Indications1. Abnormal Uterine Bleeding. ^Criteria. Approve for 2 months if Zoladex is used as an endometrial-thinning agent prior to endometrial ablation. Dosing. Approve Zoladex 3.6 mg implant once every 28 days (inserted subcutaneously into the anterior abdominal wall). 2. Breast Cancer . ^ eviCoreGonadotropin-Relea sing Hormone Agonists Implants MA Medical UM Policy Page 5 09/28/2026 Express Scripts S trategic Development, Inc., 2026 . All Rights Reserved. This document is confidential and proprietary to Express Scripts Strategic Development, Inc. Unauthorized use and distribution are prohibited.Criteria. Approve for 1 year .Dosing. Approve ONE of the following dosage regiments (inserted subcutaneously into the anterior abdominal wall) [A or B]: A) Zoladex 3.6 mg implant once every 28 days; OR B) Zoladex 10.8 mg implant once every 12 weeks. 3. Endometriosis. ^Criteria. Approve for 6 months if the patient meets the following (A and B):A) The patient is 18 years of age ; AND IC-L B) Patient has tried at least ONE of the following, unless contraindicated IC-ISGP (i, ii, or iii): i. A contraceptive (e.g., combination oral contraceptive, levonorgestrel-releasing intrauterine systems [e.g., Mirena, Liletta]); IC-ISGP OR ii. An oral progesterone (e.g., norethindrone tablets); IC-ISGP OR iii. A depo-medroxyprogesterone injection. IC-ISGP Note : An exception to the requirement for a trial of the above therapies can be made if the patient has previously used a gonadotropin-releasing hormone (GnRH) agonist (e.g., Lupron Depot) or antagonist (e.g., Orilissa). IC-ISGP Dosing. Approve Zoladex 3.6 mg implant once every 28 days (inserted subcutaneously into the anteriorabdominal wall) .4. Prostate Cancer . ^ eviCoreCriteria. Approve for 1 year.Dosing. Approve ONE of the following dosage regimens (inserted subcutaneously into the anterior abdominal wall) [A or B]: A) Zoladex 3.6 mg implant once every 28 days; OR B) Zoladex 10.8 mg implant once every 12 weeks. Other Uses with Supportive Evidence5. Gender Dysphoric/Gender-Incongruent Persons; Persons Undergoing Gender Reassignment(Female-To-Male [FTM] or Male-to-Female [MTF]). @ Criteria. Approve for 1 year .Dosing . Approve ONE of the following dosage regimens (inserted subcutaneously into the anterior abdominal wall) [A or B]: A) Zoladex 3.6 mg implant once every 28 days; OR B) Zoladex 10.8 mg implant once every 12 weeks. 6. Head and Neck Cancer Salivary Gland Tumors . @ eviCore Gonadotropin-Relea sing Hormone Agonists Implants MA Medical UM Policy Page 6 09/28/2026 Express Scripts S trategic Development, Inc., 2026 . All Rights Reserved. This document is confidential and proprietary to Express Scripts Strategic Development, Inc. Unauthorized use and distribution are prohibited.Criteria. Approve for 1 year if the patient meets the following (A and B):A) Patient has recurrent, unresectable, or metastatic disease; ANDB) Patient has androgen receptor-positive disease. Dosing. Approve Zoladex 3.6 mg implant once every 28 days (inserted subcutaneously into the anteriorabdominal wall).7. Ovarian Cancer, including Fallopian Tube Cancer and Primary Peritoneal Cancer . @ eviCoreCriteria. Approve for 1 year .Dosing. Approve Zoladex 3.6 mg implant once every 28 days (inserted subcutaneously into the anterior abdominal wall). 8. Preservation of Ovarian Function/Fertility in Patients Undergoing Chemotherapy . @ eviCoreCriteria. Approve for 1 year.Dosing . Approve ONE of the following dosage regimens (inserted subcutaneously into the anteriorabdominal wall) [A or B]:A) Zoladex 3.6 mg implant once every 28 days; OR B) Zoladex 10.8 mg implant once every 12 weeks. 9. Prophylaxis or Treatment of Uterine Bleeding or Menstrual Suppression in Patients with Hematologic Malignancy, or Undergoing Cancer Treatment, or Prior to Bone Marrow/Stem Cell Transplantation . @ eviCoreCriteria. Approve for 1 year.Dosing . Approve ONE of the following dosage regimens (inserted subcutaneously into the anteriorabdominal wall) [A or B]:A) Zoladex 3.6 mg implant once every 28 days; OR B) Zoladex 10.8 mg implant once every 12 weeks. 10. Uterine Cancer . @ eviCoreCriteria. Approve for 1 year.Dosing. Approve Zoladex 3.6 mg implant once every 28 days (inserted subcutaneously into the anterior abdominal wall). CONDITIONS NOT RECOMMENDED FOR APPROVALCoverage of Supprelin LA and Zoladex is not recommended in the following situations:Gonadotropin-Relea sing Hormone Agonists Implants MA Medical UM Policy Page 7 09/28/2026 Express Scripts S trategic Development, Inc., 2026 . All Rights Reserved. This document is confidential and proprietary to Express Scripts Strategic Development, Inc. Unauthorized use and distribution are prohibited.1. Peripheral Precocious P ubert y (also known as GnRH-independent precocious pu berty) .Children with peripheral precocious puberty do not respond to GnRH agonist therapy. 8 Treatment is directed at removing or blocking the production and/or response to the excess sex steroids, depending on the cause (e.g., surgically removing human chorionic gonadotropin-secreting tumors or using glucocorticoids to treat defects in adrenal steroidogenesis [such as classic congen ital adrenal hyperplasia]). 2. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria .Criteria will be updated as new published data are available . SOURCES OF INFORMATION1. Supprelin LA [prescribing information]. Malvern, PA : Endo; September 2025 .2. Zoladex 3.6 mg implant [prescribing information]. Deerfield, IL: TerSera Therapeutics; September 2025. 3. Zoladex 10.8 mg implant [prescribing information]. Deerfield, IL: TerSera Therapeutics; September 2025. 4. The NCCN Breast Cancer Clinical Practice Guidelines in Oncology ( version 1.2026 January 16, 2026). 20 26 National Comprehensive Cancer Network. Available at: http://www.nccn.org . Accessed on February 8, 2026. 5. Eugster EA. Treatment of central precocious puberty. JEndo Soc . 2019;3:965-972 . 6. Carel JC , Eugster EA , Rogol A , et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics . 2009 Apr;123(4):e752-62. 7. Krishna KB, Fuqua JS, Rogol AD, et al. Use of gonadotropin-releasing hormone analogs in children: update by an international consortium. Horm Res Paediatr . 2019;91:357-372. 8. The NCCN Prostate Cancer Clinical Practice Guidelines in Oncology ( version 5.2026 January 23, 2026 ). 20 26 National Comprehensive Cancer Network. Available at: http://www.nccn.org . Accessed on February 8, 2026. 9. The NCCN Drugs and Biologics Compendium. 2026 National Comprehensive Cancer Network. Available at: http://www.nccn.org . Accessed on February 8, 2026. Search term: goserelin acetate. 10. The NCCN Uterine Neoplasms Clinical Practice Guidelines in Oncology (version 2.2026 November 14, 2025). 2025 National Comprehensive Cancer Network. Available at: http://www.nccn.org . Accessed on February 8, 2026. 11. The NCCN Head and Neck Cancers Clinical Practice Guidelines in Oncology (version 1.2026 December 8, 2025). 2025 National Comprehensive Cancer Network. Available at: http://www.nccn.org . Accessed on February 8, 2026. 12. The NCCN Ovarian Cancer Clinical Practice Guidelines in Oncology (version 3.2025 July 16, 2025). 2025 National Comprehensive Cancer Network. Available at: http://www.nccn.org . Accessed on February 8, 2026. 13. Spack NP. Management of transgenderism. JAMA. 2013;309:478-484. 14. Honma Y, Monden N, Yamazaki K, et al. Yatagarasu: A single-arm, open-label, phase 2 study of apalutamide plus goserelin for patients with far locally advanced or recurrent/metastatic and androgen receptor-expressing salivary gland carcinoma [abstract]. JClin Oncol. 2022;40 (Suppl): Abstract 6079. 15. Patel M, Fojioka N, Pease DF, et al. BTCRC-HN17-111, A phase 2 trial of ADT (Goserelin) in combination with pembrolizumab for patients with advanced salivary gland tumors expressing androgen receptor [abstract]. JClin Oncol. 2022;40 (Suppl): Abstract e18091. 16. Boon E, van Boxtel W, Buter J, et al. Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in the Netherlands. Head Neck. 2018;40:605-613. 17. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guidelines. JClin Endocrinol Metab . 2017;102:3869-3903. 18. World Professional Association for Transgender Health (WPATH). Standards of Care for the health of transgender and gender diverse people (version 8). Available at: Standards of Care for the Health of Transgender and Gender Diverse People, Version 8 (tandfonline.com) . Accessed on January 9, 2026. 19. Rosenthal SM. Approach to the patient: transgender youth: endocrine considerations. JClin Endocrine Metab. 2014;99:4379-4389. 20. The NCCN Adolescent and Young Adult Oncology Clinical Practice Guidelines in Oncology (version 2.2026 February 27, 2026). 2026 National Comprehensive Cancer Network. Available at: http://www.nccn.org . Accessed on March 27, 2026. 21. Edi R, Cheng T. Endometriosis: Evaluation and treatment. Am Fam Physician. 2022;106(4):397-404. 22. Centers for Medicare and Medicaid Services, Palmetto GBA. Local Coverage Article: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs (A59160 ) (Original Effective Date 2/19/2023 , Revision Effective Date 10/1/25 ). Accessed on September 28, 2026 . 23. Centers for Medicare and Medicaid Services, Palmetto GBA. Lo cal Coverage Determination : Luteinizing Hormone-Releasing Hormone (LHRH) Analogs (L39387 ) (Original Effective Date 2/19/2023; Revision Effective Date 10/10/2024 ). Accessed on September 28, 2026 . Gonadotropin-Relea sing Hormone Agonists Implants MA Medical UM Policy Page 8 09/28/2026 Express Scripts S trategic Development, Inc., 2026 . All Rights Reserved. This document is confidential and proprietary to Express Scripts Strategic Development, Inc. Unauthorized use and distribution are prohibited.HISTORYType of Revision Summary of Changes Review DatePolicy created New Policy 05/10/2023 Policy revision Head and Neck Cancer Salivary Gland Tumors; Ovarian Cancer, includingFallopian Tube Cancer and Primary Peritoneal Cancer; Uterine Cancer. These new conditions and criteria were added to the policy. Breast Cancer: Removal of criteria related to premenopausal or perimenopausal women. Added the following dosing regimen for approval: Zoladex 10.8 mg every 12 weeks. 04/08/2024 Policy review No criteria changes. Review based on NCD surveillance review. 01/07/2025 Policy revision Removed Vant as from the policy (obsolete). Revision based on commercial policy revision02/18/2025Policy revision No criteria changes. Formatting and notation updates. 07/29/2025 Policy review No criteria changes. Review based on surveillance of LCD/LCA. 10/31/2025 Policy revision Other Uses with Supportive Evidence: Gender-Dysphoric/Gender-Incongruent Persons; Persons Undergoing Gender Reassignment (Female-To-Male or Male – To-Female) was added as a new condition of approval for Supprelin LA and Zoladex. 03/05/2026 Policy revision Preservation of Ovarian Function/Fertility in Patients Undergoing Chemotherapy; Prophylaxis or Treatment of Uterine Bleeding or Menstrual Suppression in Patients with Hematologic Malignancy, or Undergoing Cancer Treatment, or Prior to Bone Marrow/Stem Cell Transplantation : These conditions of approval were added to the policy for Zoladex. 04/28/2026 Policy revision Enometriosis : Added a criterion requiring a trial of a contraceptive, an oral progesterone, or a depo-medroxyprogesterone injection, unless contraindicated. A note was also added noting that an exception can be provided if the patient has previously used a gonadotrop in-releasing hormone agonist or antagonist. 09/28/2026
Re: Summary of Formulary/Prior Authorization Changes Effective October 1, 2026 Dear CareSource PASSE Member, Your health care is our priority. We are writing to tell you that on October 1, 2026, there w ill be changes made to Arkansas Medicaids Preferred Drug List (PDL) and CareSource PASSEs management of products not on Arkansas Medicaids PDL. A PDL is a list of preferred drugs. SUMMARY OF CHANGES TO THE ARKANSAS MEDICAID PDL EFFECTIVE OCTOBER 1, 2026: THE FOLLOWING MEDICATION(S) WILL BE PREFERRED ON THE PDL EFFECTIVE OCTOBER 1, 2026 Product Name Strength(s) Notes Bosentan (Generic for Tracleer ) tablet All Updated to preferred with criteria effective 7/28/26 Ebglyss pen, syringe All Eucrisa ointment 2% propranolol Extended Release (Generic for Inderal LA ) capsule All Took effect 5/29/26 Opzelura cream 1.5% Rhapsido tablet All Tezspire pen, syringe All Ubrelvy tablet All Vtama cream All THE FOLLOWING MEDICATION(S) WILL BE NON-PREFERRED ON THE PDLEFFECTIVE OCTOBER 1, 2026 Product Name Strength(s) Notes cimetidine (Generic for Tagamet ) tablet All Took effect 7/1/26 gabapentin (Generic for Relgaabi ) capsule 200mg Updated to non-preferred with age limit effective 6/1/26 labetalol tablet 400mg Updated to non-preferred effective 6/16/26 Migergot suppository All Tracleer tablet All Updated to non-preferred effective 9/1/26 Vigadrone powder in packet All CareSourcePASSE.com THE FOLLOWING MEDICATION(S) HAVE A CHANGE IN PRIOR AUTHORIZATION/CRITERIA ON THE PDL EFFECTIVE OCTOBER 1, 2026 Product Name Strength(s) Notes Atoncy oral solution 4mg/mL Age and quantity limit updated effective 5/29/26 Awiqli Flextouch insulin pen 700 units/mL Age limit updated effective 8/7/26 Baxfendy tablet All Quantity limit updated effective 5/25/26 and age limit updated effective 6/1/26 Bysanti tablet All Quantity limit updated effective 5/12/26 Carbzah oral solution 4mg/5mL Age limit updated effective 5/28/26 and 6/1/26 Cardamyst nasal spray All Quantity limit updated effective 4/15/26 Cavhanzah ODT All Age limit updated effective 7/14/26 Filkri syringe 300mcg/ 0.5mL Quantity limit updated effective 5/13/26 folic acid oral solution 0.2 mg/mL Age and quantity limit updated effective 5/11/26 glipizide (Generic for Glucotrol ) tablet 15 mg Quantity limit updated effective 5/7/26 haloperidol decanoate (Generic for Haldol ) vial All Criteria updated effective 5/15/26 Hepcludex vial 8.5mg Quantity limit updated effective 5/22/26 and age limit updated effective 6/1/26 isotretinoin (Generic for Absorica ) capsule All Criteria updated effective 5/29/26 lenalidomide (Generic for Revlimid ) capsule 5mg, 10mg Quantity limit updated effective 5/28/26 Linzess capsule 72mcg Age limit updated effective 6/1/26 Myrbetriq Extended Release suspension 8 mg/mL Age limit updated effective 6/15/26 Nereus capsule 85mg Age and quantity limit updated effective 5/11/26 Norliqva solution All Age limit updated effective 5/14/26 and quantity limit updated effective 4/13/26 Seroquel XR tablet 150mg Age limit updated effective 6/1/26 Skyrizi pen, syringe, on-body wearable injector All Age limit updated effective 6/22/26 tapentadol (Generic for Nucynta ) oral solution 20mg/mL Age limit updated effective 7/20/26 tofacitinib (Generic for Xeljanz ) solution 1mg/mL Quantity limit updated effective 6/3/26 topiramate Extended Release (Generic for Trokendi XR) sprinkle capsule 150mg Quantity limit updated effective 5/12/26 CareSourcePASSE.com Product Name Strength(s) Notes Tryngloza autoinjector 50mg/0.8mL Age limit updated effective 6/26/26 Ranexa Extended Release tablet All Criteria updated effective 5/12/26 Saphnelo syringe 120 mg / 0.8 mL Quantity limit updated effective 5/14/26 Zepbound pen injector All Quantity limit updated effective 3/2/26 Zolymbus eye drops 0.01 % Age limit updated effective 5/6/26 Zoryve cream 0.3% Age limit updated effective 7/1/26 What should you do?First, talk to your prescriber. There are a few ways you and your prescriber can find medication information: You can look on our website at CareSourcePASSE.com . On the Members page, und er Tools & Resources click on Find My Prescriptions. Or, call Member Services at 1-833-230-2005 (TDD/TTY: 711). We are here to help. Member Services is open Monday through Friday, 8 a.m. to 5 p.m. Central Time (CT). Sincerely, CareSource PASSE AR-PAS-M-1135300-V.20 DHS Approved: 2/23/2022 CareSourcePASSE.com
© Copyright CareSource 2026. All rights reserved.
System Details